BLS Directors’ Performance Rights Vest, Lifting Shareholdings
BLS Pharmaceuticals directors Jason Hine and Samuel Watson reported shares issued after FY2026 performance rights vested on achievement of milestones and performance hurdles. Hine’s indirect ordinary shareholding increased, while Watson’s direct shareholding rose; both directors’ performance-rights balances fell.
Closing price · 2026-10-27: $1.00 · +5.26%